



Mycobacterium tuberculosis prosthetic joint infections: A case series and literature review



Fabrice Uhel^{a,b,c}, Gregory Corvaisier^d, Yves Poinignon^d, Catherine Chirouze^e, Guillaume Beraud^f, Olivier Grossi^g, Nicolas Varache^h, Cédric Arvieux^{a,c}, Rozenn Le Berreⁱ, Pierre Tattevin^{a,c,*}, for the Groupe d'Epidémiologie et Recherche en Infectiologie Clinique Centre-Ouest (GERICCO)

^a Maladies Infectieuses et Réanimation Médicale, CHU Rennes, CHU Pontchaillou, 2 rue Henri Le Guilloux, F-35033 Rennes, France

^b Faculté de Médecine, Inserm, U1236, F-35043 Rennes, France

^c Faculté de Médecine, Inserm, CIC-1414, Université Rennes 1, F-35043 Rennes, France

^d Médecine Interne, CH Bretagne Atlantique, F-56017 Vannes, France

^e CNRS 6249, Université de Bourgogne-Franche-Comté, CHRU Besançon, F-25030 Besançon, France

^f Maladies Infectieuses, CHU Poitiers, F-86021 Poitiers, France

^g Médecine Interne – Infectiologie, Nouvelles Cliniques Nantaises, F-44277 Nantes, France

^h Maladies Infectieuses et Tropicales, CH Le Mans, F-72037 Le Mans, France

ⁱ Médecine Interne et Pneumologie, CHRU de la Cavale Blanche, F-29609 Brest, France

ARTICLE INFO

Article history:

Accepted 8 August 2018

Available online 20 August 2018

Keywords:

Prosthetic joint

Mycobacterium tuberculosis

Arthroplasty

Debridement

Antituberculosis drug

SUMMARY

Objectives: We aimed to characterize diagnosis, management, and outcome of *Mycobacterium tuberculosis* prosthetic joint infections (PJI).

Methods: Cases of *M. tuberculosis* PJI documented in 7 referral French centers were retrospectively reviewed. Data were collected from medical files on a standardized questionnaire. We performed a literature review using the keywords 'prosthetic joint', and 'tuberculosis'.

Results: During years 1997–2016, 13 patients (8 males, 5 females, median age 79 years [range, 60–86]) had documented *M. tuberculosis* PJI, involving hip ($n=6$), knee ($n=6$), or shoulder ($n=1$). Median time from arthroplasty to diagnosis was 9 years [0.4–20]. The diagnosis was obtained on joint aspirates ($n=9$), or synovial tissue ($n=4$). PCR was positive in all cases tested (5/5). Median duration of antituberculosis treatment was 14 months [6–32]. Nine patients underwent surgery: debridement ($n=4$), resection arthroplasty ($n=3$), and revision arthroplasty (1-stage exchange, $n=2$). PJI was controlled in 12 patients. Seventeen additional cases of documented *M. tuberculosis* PJI have been reported, with a favorable outcome in 79% (11/14) of patients with no surgery, 85% (11/13) with debridement, 86% (19/22) with revision arthroplasty, and 81% (17/21) with resection (NS).

Conclusions: *M. tuberculosis* PJI can be controlled with prolonged antituberculosis treatment in most cases, with or without surgical treatment.

© 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Introduction

Mycobacterium tuberculosis is a rare cause of prosthetic joint infection (PJI), as most countries with high prevalence of tuberculosis have limited access to prosthetic arthroplasty. Moreover, as the diagnosis relies on specific tests not routinely performed for PJI, a significant proportion of *M. tuberculosis* PJI cases probably remain undiagnosed.^{1,2} Tuberculosis PJI may result from the hematogenous

spread of an extra-articular focus of active tuberculosis, or from the local reactivation of latent tuberculosis, even in patients without previously known history of tuberculosis.³ *M. tuberculosis* PJI may also arise from an active tuberculosis of the native joint, mimicking osteoarthritis, undiagnosed by the time of arthroplasty.⁴ Given the limited number of cases reported to date, the optimal strategy for the management of *M. tuberculosis* PJI is still controversial, as clinical practice guidelines for tuberculosis⁵ and for PJI,⁶ provide no specific recommendation for *M. tuberculosis* PJI. In particular, whether the prosthetic joint needs to be removed is unclear. This question is of importance since *M. tuberculosis* PJI frequently occur in elderly patients with poor general condition and

* Corresponding author at: Maladies Infectieuses et Réanimation Médicale, CHU Rennes, CHU Pontchaillou, 2 rue Henri Le Guilloux, F-35033 Rennes, France.
E-mail address: pierre.tattevin@chu-rennes.fr (P. Tattevin).

high surgical risk.^{3,7} To better characterize *M. tuberculosis* PJI, we report our own experience of 13 consecutive cases, and performed a literature review, with a focus on management and outcome.

Methods

We performed a retrospective study of all patients with documented *M. tuberculosis* PJI managed from 1997 to 2016 in seven referral hospitals, members of a clinical research network, the *Groupe d'Epidémiologie et Recherche en Infectiologie Clinique Centre-Ouest* (GERICCO), in Western France. During the study period, all patients diagnosed with a *M. tuberculosis* PJI in these centers were managed by a multidisciplinary team including specialists in infectious diseases, orthopedic surgery, and microbiology. We only enrolled patients with at least one PJI sample (i.e., joint aspirates or synovial tissue) positive for *M. tuberculosis* by culture or PCR. Patients who were previously diagnosed with native joint tuberculosis by the time of arthroplasty were not enrolled. Cases were identified through computerized databases from the microbiology departments and the infectious diseases units of the participating sites. Clinical, biological, and microbiological data were extracted from medical charts through a standardized questionnaire, as well as the type and dates of PJI surgery(ies), antituberculosis drugs, and outcome. Physicians in charge were requested to categorize the outcome as favorable, unknown, or not favorable. The study was approved by the Rennes University Hospital Institutional Review Board. For the literature review, we searched Medline and Embase for articles in English or French published before January 2018, using the keywords “prosthetic joint infection” and “tuberculosis”.

Results

Between 1997 and 2016, 13 patients (8 males, 5 females, median age 79 years [range, 60–86]) were diagnosed with *M. tuberculosis* PJI in the seven participating centers. Patients characteristics are presented in Table 1. Six patients (46%) had been previously diagnosed with active tuberculosis, pulmonary ($n=5$), or disseminated ($n=1$), 2–56 years before the diagnosis of *M. tuberculosis* PJI. Major comorbidities were colon cancer ($n=2$), diabetes ($n=1$), and rheumatoid arthritis ($n=1$). PJI involved hip ($n=6$), knee ($n=6$), or shoulder ($n=1$). Median duration from arthroplasty to PJI diagnosis was 9 years [range, 0.4–20]. Main symptoms were pain ($n=9$), fever ($n=6$), local inflammation ($n=6$), and weight loss ($n=6$). Median white blood cells count was 6.3 G/L [range, 2.3–8.8], median CRP level was 80 mg/L [range, 14–183]). The diagnosis of *M. tuberculosis* PJI was obtained on joint aspirates ($n=9$), or synovial tissue ($n=4$). Acid-fast bacilli were observed on microscopic examination in 6 cases, and culture was positive for *M. tuberculosis* in 11 cases. In 4 patients, tuberculosis was also documented by respiratory samples. Four patients (31%) had another active localization of tuberculosis by the time of *M. tuberculosis* PJI, including pulmonary ($n=2$), hepatic ($n=2$), pericardial, splenic, and pleural (one patient each). Nine cases were multi-susceptible tuberculosis, and two were resistant to isoniazid. Drug susceptibility testing could not be performed in two cases who were only documented through PCR. Of note, PCR was positive in all cases tested (5/5).

Treatment included antituberculosis drugs for 12 patients (median duration, 14 months [range, 6–32]), and surgery for nine patients: debridement ($n=4$), definitive resection arthroplasty ($n=3$), and revision arthroplasty (1-stage exchange, $n=2$). PJI could be controlled in 12 patients. Three patients died (23%), including one death attributable to tuberculosis, in a 71-year old man who died with fever, cachexia, and untreated *M. tuberculosis* PJI, as the diagnosis of tuberculosis was obtained post-mortem. The median duration of follow-up for the 10 patients who survived

was 21 months after *M. tuberculosis* PJI diagnosis, and 7 months after tuberculosis treatment discontinuation [range, 0–8].

The literature review identified 70 additional observations of *M. tuberculosis* PJI (Table 2).^{2,4,8–54}

They were 39 females and 31 males, with a median age of 68 years [range, 27–92]. History of previous tuberculosis was reported in 33% of cases. PJI occurred in hip ($n=38$), knee ($n=30$), shoulder ($n=1$), or wrist ($n=1$), with a median duration of one year (range, 0–38 years) between arthroplasty, and *M. tuberculosis* PJI diagnosis. Fourteen patients (20%) had at least one other site of active tuberculosis by the time of *M. tuberculosis* PJI diagnosis, including pulmonary ($n=9$), urinary ($n=2$), and adrenal gland, elbow arthritis, vertebral osteomyelitis, neuro-meningeal, disseminated tuberculosis (one patient each). Tuberculosis was mostly documented by synovial tissue histology ($n=31$), synovial tissue culture ($n=26$), joint aspirate culture ($n=19$), or sputum culture ($n=8$). Microscopic examination had a low yield, either in synovial tissue ($n=5$), or in joint aspirates ($n=2$). Drug susceptibility testing was available for only 17 isolates, including 13 multi-susceptible, two streptomycin-resistant, one isoniazid-resistant, and one multidrug-resistant. Treatment included antituberculosis drugs for a median duration of 12 months [range, 5–36]. The outcome was reported as favorable in 11/14 patients (79%) who had no surgery, 11/13 patients (85%) who underwent debridement with prosthesis retention, 19/22 patients (86%) who had prosthesis revision (one- or two-stage exchange), and 17/21 patients (81%) who had prosthesis resection with no reimplantation (NS).

Discussion

The main findings of this case series and the literature review on *M. tuberculosis* PJI are the following: (i) *M. tuberculosis* PJI occurred mostly in elderly patients, with similar numbers in males and females; (ii) median time from arthroplasty to *M. tuberculosis* PJI diagnosis was one year in our case series as well as in the literature, with a large variability (from <1 month, to 38 years); (iii) past medical history of active tuberculosis was found in only 33–45% of cases; (iv) by the time of *M. tuberculosis* PJI diagnosis, 20–33% of patients had at least one other localization of active tuberculosis, predominantly the lungs; (v) the diagnosis of *M. tuberculosis* PJI was usually obtained on synovial tissue and/or joint aspirates; (vi) surgery was not a major prognostic factor, with similar rates of favorable outcome in patients who underwent resection arthroplasty, revision arthroplasty, debridement with prosthesis retention, and even in patients who had no surgery.

The latter was quite unexpected, given that surgery is an essential component of the management of PJI, when the usual pathogens are involved (e.g., staphylococci, streptococci, enterococci, Enterobacteriaceae, *Pseudomonas aeruginosa*, anaerobes)⁶. However, when combining our case series and literature data, the majority of patients with documented *M. tuberculosis* PJI who received no surgery had a favorable outcome (14/15, 93%). Although these patients only represent 20% of *M. tuberculosis* PJI, this suggests that prolonged antituberculosis treatment may be curative in a substantial proportion of cases. The second discrepancy with the paradigms for the management of PJI is the high rate of success in patients with late PJI in whom prosthesis was retained. Indeed, this situation is usually considered as a strong indication for revision arthroplasty, either one- or two-stage. However, in six cases of our series and 12 cases in the literature,^{2,9,22,25,34,41,42,46,49} *M. tuberculosis* PJI developed between 12 months and 11 years after arthroplasty, but could still be controlled without removal of the prosthesis, with a management strategy including prolonged antituberculosis treatment, with or without debridement. For patients who underwent revision arthroplasty, although no definitive conclusion can be drawn from such a retrospective observational

Table 1
Characteristics of patients diagnosed with *Mycobacterium tuberculosis* prosthetic joint infection (PJI) at our institutions.

	Sex, age (years)	Prior active tuberculosis (TB)	Prosthetic joint infected	Time from arthroplasty to infection	Documentation of <i>M. tuberculosis</i> PJI	Other localizations	Anti-TB drugs (duration, months)	Surgical treatment	Outcome (post-treatment follow-up)
Patient 1	M, 79	Pulmonary TB during childhood	Knee	7 years	Joint aspirate (Ziehl-Neelsen, and culture)	Lung, pericardium, liver	INH/RMP (12), EMB (4), PZA (2)	No surgery	Good (1 year)
Patient 2	M, 60	Possible pulmonary TB during childhood	Hip	5 years	Joint aspirate (Ziehl-Neelsen, and culture)	–	INH/RMP (18), EMB (14)	No surgery	Good (2 years)
Patient 3	M, 84	Pulmonary TB 35 years before	Knee	11 years	Synovial tissue (PCR, and culture)	Liver, spleen	INH/RMP (9), EMB (2)	Debridement	Signs of infection resolved, sudden death
Patient 4	M, 79	Pulmonary TB 3 years before	Hip	4 years	Joint aspirate (PCR, and culture)	–	RMP/PZA (15), EMB (3), INH (1)*	Revision arthroplasty	Signs of infection resolved, Died of poor general condition
Patient 5	M, 86	No	Knee	9 years	Joint aspirate (PCR)	–	INH/RMP/OFX (6), EMB (4)	Resection arthroplasty	Good (3 months)
Patient 6	F, 85	No	Knee	14 years	Joint aspirate (Ziehl-Neelsen, and culture)	–	INH/RMP (12), EMB (2), PZA (1)	Resection arthroplasty	Good (2 months)
Patient 7	F, 82	No	Knee	9 years	Synovial tissue (Ziehl-Neelsen, and culture)	–	INH/RMP (15), PZA (0.5)	Resection arthroplasty	Good (6 months)
Patient 8	M, 71	Pleural TB 1 year before	Hip	20 years	Joint aspirate (Ziehl-Neelsen, and culture)	Pleura	Untreated	Untreated	Died before diagnosis
Patient 9	F, 64	No	Shoulder	5 months	Joint aspirate (Ziehl-Neelsen, PCR, and culture)	–	INH/RMP (32), PZA (2)	Debridement	Good (3 months)
Patient 10	F, 81	No	Hip	4 years	Joint aspirate (culture)	Lungs	INH/RMP (17), EMB/PZA (2)	Debridement	Good (1 year)
Patient 11	M, 61	No	Hip	2 years	Synovial tissue (culture)	–	INH/RMP (9), EMB (3)	Debridement	Good (8 year)
Patient 12	M, 69	Disseminated TB 2 years before	Hip	10 years	Synovial tissue (PCR)	–	INH/RMP (24), EMB/PZA (6)	Revision arthroplasty	Good (6 months)
Patient 13	F, 84	No	Knee	3 years	Joint aspirate (culture)	–	INH/RMP (12), EMB/PZA (2)	No surgery	Good (still on treatment)

EMB, ethambutol; F, female; INH, isoniazid; M, male; OFX, ofloxacin; PCR, polymerase chain reaction; PZA, pyrazinamide; RMP, rifampicin; TB, tuberculosis.

* For this patient, *M. tuberculosis* isolate had primary high-level resistance to INH on drug susceptibility testing.

Table 2
Cases of *Mycobacterium tuberculosis* prosthetic joint infection reported in the literature.

Author, year	Sex, age (years)	Prior active TB	Prosthetic joint infected	Time from arthroplasty to infection	Documentation of <i>M. tuberculosis</i> PJI	Other localizations	Anti-TB drugs (duration, months)	Surgical treatment	Outcome (post-treatment follow-up)
McLaughlin, 1977 ⁸	M, –	No	Hip	<1 month	NS	–	NS (NS)	No surgery	NS
McCullough, 1977 ⁹	F, 77	Possible lymph nodes TB	Hip	7 years	Synovial tissue (culture)	–	INH/RMP (18), SM (2)	Debridement	Good (6 months)
Wolfgang, 1978 ¹⁰	F, 70	No	Hip	4 months	Synovial tissue (histology, culture)	–	NS (NS)	No surgery	NS
Mouterde, 1978 ¹¹	M, 37	No	Hip	12 months	NS	–	NS (NS)	Resection arthroplasty	NS
Besser, 1980 ¹²	M, 65	No	Knee	<1 month	Synovial tissue (histology)	–	NS (12)	No surgery	Good (1 year)
Carbon, 1981 ¹³	F, 40	No	Hip	8 months	NS	–	NS (NS)	Resection arthroplasty	Good (5 years)
Carbon, 1981 ¹³	M, 74	No	Hip	2.5 years	NS	–	NS (NS)	Resection arthroplasty	Good (5 years)
Olsson, 1981 ¹⁴	M, 64	No	Hip	2 years	NS	–	NS (NS)	Revision arthroplasty (partial)	NS
Bryan, 1982 ¹⁵	F, 72	No	Knee	8 years	Joint aspirate (culture)	Elbow arthritis	INH/RMP/PZA (24)	Arthrodesis	Good (3 years)
Hecht, 1983 ¹⁶	M, 27	Possible hip TB	Hip	3 months	Joint aspirate (culture)	–	INH/EMB (NS)	Resection arthroplasty	Good (1 year)
Zeiger, 1984 ¹⁷	F, 40	NA	Knee	4 years	Synovial tissue (culture)	–	NS (NS)	Resection arthroplasty	NS
Levin, 1985 ¹⁸	F, 81	No	Hip	4 years	NS	–	INH/RMP (36), SM (3.5)	Resection arthroplasty	Good (2.5 months)
Wolfgang, 1985 ¹⁹	M, 61	No	Knee	13 months	Joint aspirate (culture)	–	INH/RMP (24)	Staged exchange	Good (1 year)
Delrieu, 1986 ²⁰	F, 69	No	Hip	12 months	NS	–	NS (NS)	Resection arthroplasty	Good (2 years)
Delrieu, 1986 ²⁰	F, 75	No	Hip	10 years	NS	–	NS (NS)	Resection arthroplasty	Good (3 years)
Lin, 1986 ²¹	F, 70	No	Hip	8 months	NS	–	NS (NS)	No surgery	Good (4 years)
Lin, 1986 ²¹	F, 49	No	Hip	8 months	Synovial tissue (histology)	–	NS (NS)	No surgery	Good (3 years)
Wray, 1987 ⁴	M, 62	No	Knee	<1 month	Synovial tissue (histology, culture)	Lungs	INH/RMP/EMB (12)	No surgery	Good (5 years)
Wray, 1987 ⁴	M, 63	No	Knee	<1 month	Synovial tissue (histology) + Sputum (culture)	Lungs	INH/RMP (12)	No surgery	Good (1.5 years)
Eskola, 1988 ²²	M, 47	Possible knee TB	Knee	18 months	Joint aspirate (culture)	–	INH/RMP/EMB (12)	Debridement	Good (2 years)
Baldini, 1988 ²³	M, 61	No	Hip	2 years	Synovial tissue (culture)	–	NS (NS)	Resection arthroplasty	Good (4 months)
Gale, 1991 ²⁴	M, 67	No	Knee	<1 month	Synovial tissue (histology) + Sputum (culture)	Lungs	INH/RMP (12), EMB (6)	No surgery	Good (10 years)
Callaghan and Vail, 1994 ²⁵	M, 79	No	Knee	10 years	NS	–	NS (NS)	Revision arthroplasty	NS
Lusk, 1995 ²⁶	F, 75	No	Knee	15 years	Synovial tissue (histology, culture)	–	INH/PZA (6), RMP (1), EMB (5)	Resection arthroplasty	Died (6 months)

(continued on next page)

Table 2 (continued)

Author, year	Sex, age (years)	Prior active TB	Prosthetic joint infected	Time from arthroplasty to infection	Documentation of <i>M. tuberculosis</i> PJI	Other localizations	Anti-TB drugs (duration, months)	Surgical treatment	Outcome (post-treatment follow-up)
Tokumoto, 1995 ²⁷	F, 72	No	Hip	3 years	Synovial tissue (culture)	–	INH/RMP (12)	Resection arthroplasty	NS
Tokumoto, 1995 ²⁷	F, 71	Hip TB	Knee	20 months	Joint aspirate (culture)	–	INH/EMB (18)	Resection arthroplasty	Good (8 years)
Tokumoto, 1995 ²⁷	F, 70	No	Knee	38 years	Joint aspirate (culture)	–	INH/RMP (12)	Resection arthroplasty	Good (2 years)
Ueng, 1995 ²⁸	M, 40	No	Hip	15 years	Joint aspirate (culture)	Lungs	INH/RMP/EMB (12)	Resection arthroplasty	Good (> 1 year)
Ueng, 1995 ²⁸	M, 62	No	Hip	18 months	Synovial tissue (culture)	Lungs	INH/RMP/PZA (24)	Revision arthroplasty	Good (3 years)
Kreder, 1996 ²⁹	F, 66	No	Hip	4 years	NS	–	INH/EMB/PZA (9), RMP (NS)	Revision arthroplasty (partial)	Good (18 months)
Spinner, 1996 ²⁵	F, 70	No	Knee	4.5 years	Synovial tissue (culture)	–	INH (NS), RMP/EMB (12)	Debridement	Good (2.5 years)
Carlsson, 1997 ³⁰	M, 75	Knee TB	Hip	4 months	Synovial tissue (histology, culture, PCR)	–	INH/RMP (12), PZA (2)	Revision arthroplasty	Good (6 months)
Berbari, 1998 ³¹	F, 44	No	Hip	23 years	NS	–	INH/EMB (16)	Resection arthroplasty	Good (8 years)
Berbari, 1998 ³¹	M, 60	No	Hip	30 years	NS	–	INH/EMB (19), RMP (1)	Resection arthroplasty	Good (10 years)
Berbari, 1998 ³¹	F, 52	No	Hip	10 years	NS	–	INH/RMP (15)	Staged exchange	Good (7 years)
Krappel, 2000 ³²	F, 67	Peritoneal and pleural TB	Hip	2 months	Synovial tissue (histology)	–	INH/RMP (12), SM (3), PZA (NS)	Revision arthroplasty (partial)	Good (2.5 years)
Hugate, 2002 ³³	M, 71	Knee TB	Hip	5 months	Synovial tissue (culture)	–	INH/RMP/EMB (12), PZA (NS)	Debridement	Good (1.2 years)
Boeri, 2003 ³⁴	F, 55	No	Hip	2 years	Joint aspirate (culture)	–	INH/RMP (17), EMB/PZA (4)	No surgery	Good (9 months)
Boeri, 2003 ³⁴	F, 47	Possible hip TB	Hip	3 years	Synovial tissue (culture)	–	INH/RMP (6), EMB/PZA (3)	Revision arthroplasty	Good (8 years)
Fernandez-Valencia, 2003 ³⁵	M, 78	No	Hip	6 months	Synovial tissue (histology)	–	INH/RMP (9), EMB (3)	Resection arthroplasty	Good (6 years)
Al Shaikh, 2003 ³⁶	F, 73	No	Knee	8 months	Synovial tissue (culture)	–	INH/RMP/PZA (12), EMB (9)	Debridement, delayed arthrodesis	Good (1 year)
Marmor, 2004 ³⁷	M, 66	No	Knee	2 months	Joint aspirate, blood (culture)	Disseminated	INH/RMP/PZA (6)	2-stage revision arthroplasty	Good (5 years)
Marmor, 2004 ³⁷	F, 65	Possible hip TB	Knee	3 months	Joint aspirate (culture)	Urinary tract	INH/RMP/PZA (6)	2-stage revision arthroplasty	Good (7 years)
Marmor, 2004 ³⁷	F, 77	No	Knee	4 months	Joint aspirate (culture)	–	INH/EMB/PZA (8)	Debridement	Good (1.5 years)
Kaya et al, 2006 ³⁸	F, 72	No	Hip	9 years	Synovial tissue (culture)	Lungs	INH/EMB/PZA (NS)	Resection arthroplasty	Good (6 months)
Kadokia, 2007 ³⁹	F, 85	No	Knee	<1 month	Joint aspirate (Ziehl-Neelsen)	Lungs	NS (6)	No surgery	Good (NS)
Khater, 2007 ⁴⁰	F, 75	No	Knee	3 months	Synovial tissue (histology, culture)	–	INH/EMB (18), RMP (NS)	Resection arthroplasty	Good (18 months)

(continued on next page)

Table 2 (continued)

Author, year	Sex, age (years)	Prior active TB	Prosthetic joint infected	Time from arthroplasty to infection	Documentation of <i>M. tuberculosis</i> PJI	Other localizations	Anti-TB drugs (duration, months)	Surgical treatment	Outcome (post-treatment follow-up)
Shanbhag, 2007 ⁴¹	F, 59	No	Hip	15 months	Joint aspirate (culture)	–	RMP/EMB/PZA (12)	Debridement	Good (1.5 years)
Wang, 2007 ⁴²	M, 72	Pulmonary TB	Knee	3 years	Synovial tissue (culture)	Lungs	INH/RMP/EMB/PZA (0.7)	Debridement	Died (1 month)
De Haan, 2008 ⁴³	F, 75	Knee TB	Knee	3 months	Synovial tissue (culture)	–	INH/RMP/EMB/PZA (9)	Debridement	Good (NS)
Marschall, 2008 ⁴⁴	M, 48	No	Knee	9 months	Joint aspirate (culture)	Lungs, Neuro-meningeal	INH/EMB/PZA (1), MOX (0.5), RMP (0.5)	No surgery	Died (1 month)
Lee, 2009 ⁴⁵	F, 79	No	Knee	2 months	Synovial tissue (histology)	–	INH/RMP/EMB/PZA (12)	Debridement	Good (13 months)
Neogi, 2009 ⁴⁶	F, 73	No	Knee	14 years	Synovial tissue (PCR)	–	INH/RMP (18), EMB (4), PZA (7)	No surgery	Good (3 years)
Upton, 2009 ⁴⁷	M, 39	CNS, urinary, joint TB	Hip	4 years	Joint aspirate (culture)	Vertebral osteomyelitis, Urinary tract	MOX/RMP (31), AMK/CS (2), PZA (4)	2-stage revision arthroplasty	Good (1.7 years)
Mete, 2012 ⁴⁸	F, 32	No	Hip	5 years	Synovial tissue (culture)	–	INH/RMP (12), EMB/PZA (2)	2-stage revision arthroplasty	Good (1 year)
De Nardo, 2012 ⁴⁹	F, 67	Possible pulmonary TB	Hip	16 months	Joint aspirate (PCR)	Adrenal glands	INH/RMP (> 18), EMB/PZA (3)	Debridement	Good (1 year)
Klein, 2012 ⁵⁰	F, 36	Genital TB	Knee	11 months	Synovial tissue (culture)	–	INH/RMP/EMB/PZA/MOX (19)	2-stage revision arthroplasty	Good (3 years)
Carrega, 2013 ⁵¹	F, 92	No	Hip	3 years	Synovial tissue (culture)	–	INH/EMB (9), RMP (1), LVX (NS)	Revision arthroplasty	Good (6 months)
Carrega, 2013 ⁵¹	M, 68	No	Wrist	2 years	Synovial tissue (culture)	–	INH/RMP (14), EMB/PZA (2)	Revision arthroplasty	Infection cured, but functional impairment (NS)
Carrega, 2013 ⁵¹	F, 79	No	Hip	<1 month	Synovial tissue (culture)	–	INH/RMP/EMB (5)	2-stage revision arthroplasty	Good (1 year)
Carrega, 2013 ⁵¹	F, 72	No	Hip	7 years	Synovial tissue (culture)	–	INH/RMP (12), PZA (2)	2-stage revision arthroplasty	Good (1 year)
Carrega, 2013 ⁵¹	F, 80	No	Knee	<1 month	Synovial tissue (histology, culture)	–	INH/RMP (14), PZA (2)	2-stage revision arthroplasty	Good for TB, but died of heart attack (6 months)
Harwin, 2013 ⁵²	F, 60	No	Knee	7 months	Synovial tissue (culture)	–	INH/RMP (21), EMB/PZA (12)	Revision arthroplasty	Good (2 years)
Tekin Koruk, 2013 ⁵³	M, 55	No	Knee	20 days	Joint aspirate (culture)	–	INH/RMP (12), EMB/PZA (2)	No surgery	Good (18 months)
Seng, 2016 ²	5 cases	Yes (3/5)	Hip (4/5) Knee (1/5)	34 months (mean)	NS	–	NS (mean 11)	No surgery (1/5) Debridement (1/5) 2-stage revision arthroplasty (3/5)	Good: 4/5 (mean, 24 months); one patient died of disseminated TB
von Keudell, 2016 ⁵⁴	M, 84	Pulmonary TB	Knee	5 months	NS	–	INH/RMP (> 15), EBB/PZA (12)	Revision arthroplasty (partial)	Good (1.3 years)

AMK, amikacin; CNS, central nervous system; CS, cycloserine; d, days; EMB, ethambutol; F, female; INH, isoniazid; LVX, levofloxacin; M, male; mo, month(s); MOX, moxifloxacin; NS, not specified; OFX, ofloxacin; PCR, polymerase chain reaction; PZA, pyrazinamide; RMP, rifampicin; SM, streptomycin; TB, tuberculosis; y, year(s).

study, it must be outlined that one-stage revision arthroplasty was successful in 12/12 cases (two cases of our series, and 10 cases in the literature^{25,28–30,32,34,51,52,54}).

These data suggest that basic rules for the management of *M. tuberculosis* PJI may differ from those usually applied for PJI due to other pathogens, with less emphasis on the timing of, and on the requirement for, surgical treatment. This may be of importance for the population of patients with *M. tuberculosis* PJI, mostly elderlies (median age, 79 years in our series), with comorbidities: when surgical treatment carries a high risk of severe complications or is declined by the multidisciplinary team and/or the patient himself, our study suggests that the outcome may still be favorable with prolonged antituberculosis treatment. This lower importance of surgery in the management of *M. tuberculosis* PJI may be related to the peculiar biology of *M. tuberculosis*, characterized by a much longer doubling time as compared to usual pathogens (e.g., 20–40 min for *Staphylococcus aureus*, and 20 h for *M. tuberculosis*). In addition, although *M. tuberculosis* may produce biofilms,⁵⁵ two *in vitro* studies on spinal implants found that the capacity of *M. tuberculosis* for adherence and biofilm formation is dramatically reduced as compared to the usual suspects for PJI, *S. aureus*, and *S. epidermidis*.^{56,57} Prolonged antituberculosis regimen including rifampicin, one of the most active antibacterials in biofilm, for a median duration of 14 months in our series and 12 months in the literature, may be curative even in the absence of surgery, for *M. tuberculosis* PJI. This doesn't imply that surgery is of no interest in the management of *M. tuberculosis* PJI, given that we could not reliably evaluate the functional outcome, due to the heterogeneity of follow-up. Surgery is most likely beneficial in specific situations such as prosthetic joint loosening (requiring exchange arthroplasty), or voluminous collection (requiring debridement and drainage). In addition, our study was not powered to analyze whether surgery could reduce the risk of late relapses.

This study has limitations. Firstly, due to its multicenter retrospective design over a long period of time (20 years), our case series has multiple potential biases: data collection and follow-up were not standardized, and the management probably differed not only from one center to another, but also over time. However, the participating centers were involved in active collaboration within the GERICO network during the study period, and patients were managed in line with French guidelines for complex osteo-articular infections and for tuberculosis, so that differences in patient management were limited. Secondly, although this case series is larger than any other case series of *M. tuberculosis* PJI published to date, sample size remains limited. Thirdly, literature review is subject to publication bias, as successful cases are more likely to be submitted for publication and accepted, as compared to failures. Finally, as the follow-up was not standardized, the data available only allows to categorize the outcome as favorable, unknown, or not favorable. Due to the heterogeneous outcome assessment in our case series and in the literature, and the propensity of *M. tuberculosis* to remain latent over decades, we are unable to differentiate patients in whom tuberculosis was cured, or only controlled. However, our case series included all cases of *M. tuberculosis* PJI documented within the GERICO network during the study period, and may be considered as representative of *M. tuberculosis* PJI characteristics, management, and outcome in our area.

In conclusion, this case series and literature review suggest that the paradigms for management of *M. tuberculosis* PJI may differ from that of PJI related to other pathogens: The outcome may be favorable in most cases with prolonged antituberculosis treatment, including for patients in whom surgery could not be performed.

Funding

No funding was received for this study.

Conflicts of interest

None.

Authorship

All authors had access to the data and participated in preparation of the manuscript.

References

- Zumla A, Raviglione M, Hafner R, Fordham von Reyn C. Tuberculosis. *N Engl J Med* 2013;**368**:745–55.
- Seng P, Honnorat E, Loffeier V, Drancourt M, Stein A. Mycobacterium tuberculosis and prosthetic joint infection. *Lancet Infect Dis* 2016;**16**:894.
- Veloci S, Mencarini J, Lagi F, Beltrami G, Campanacci DA, Bartoloni A, et al. Tubercular prosthetic joint infection: two case reports and literature review. *Infection* 2017;**46**:55–68.
- Wray CC, Roy S. Arthroplasty in tuberculosis of the knee: two cases of missed diagnosis. *Acta Orthop Scand* 1987;**58**:296–8.
- Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of america clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016; 63:e147–e195.
- Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America. *Clin Infect Dis* 2012; 56:e1–e25.
- Riccio G, Sendi P. What antibiotic therapy and duration should be used in SSI/PJI caused by Mycobacterium tuberculosis? [G-122]. In: Proceedings of the Second International Consensus Meeting on Prosthetic Joint Infection, Philadelphia, Pennsylvania; 2018 July 25–27.
- McLaughlin RE, Whitehill R. Evaluation of the painful hip by aspiration and arthrography. *Surg Gynecol Obstet* 1977;**144**:381–6.
- McCullough CJ. Tuberculosis as a late complication of total hip replacement. *Acta Orthop Scand* 1977;**48**:508–10.
- Wolfgang GL. Tuberculosis joint infection. *Clin Orthop Relat Res* 1978:257–63.
- Mouterde P, Deburge A. Tuberculosis infection after total hip replacement. Report of a case (author's transl). *Rev Chir Orthop Reparatrice Appar Mot* 1978;**64**:171–4.
- Besser MI. Total knee replacement in unsuspected tuberculosis of the joint. *Br Med J* 1980;**280**:1434.
- Carbon C, Brion NV, Darcy M, Thomas M. Tuberculous infection of total hip prosthesis: report on two cases (author's transl). *Ann Med Inter* 1980;**132**:124–5.
- Olsson SS. Tuberculous infection after hip replacement. *Lakartidningen* 1981;**78**:1890–1.
- Bryan WJ, Doherty JH, Sculco TP. Tuberculosis in a rheumatoid patient. A case report. *Clin Orthop Relat Res* 1982:206–8.
- Hecht RH, Meyers MH, Thornhill-Joyes M, Montgomerie JZ. Reactivation of tuberculous infection following total joint replacement. A case report. *J Bone Jt Surg Am* 1983;**65**:1015–16.
- Zeiger LS, Watters W, Sherk H. Scintigraphic detection of prosthetic joint and soft tissue sepsis secondary to tuberculosis. *Clin Nucl Med* 1984;**9**:638–9.
- Levin ML. Military tuberculosis masquerading as late infection in total hip replacement. *Md Med J* 1985;**34**:153–5.
- Wolfgang GL. Tuberculosis joint infection following total knee arthroplasty. *Clin Orthop Relat Res* 1985:162–6.
- Delrieu F, Slaoui O, Evrard J, Amor B. Mycobacterial infection of the hip following total prosthesis. Study of 6 cases. *Rev Rhum Mal Osteoartic* 1986;**53**:113–18.
- Lin E, Oliver S, Caspi I, Ezra E, Bubis JJ, Nerubay J. Hip arthroplasty in quiescent mycobacterial infection of hip. *Orthop Rev* 1986;**15**:232–6.
- Eskola A, Santavirta S, Kontinen YT, Tallroth K, Lindholm ST. Arthroplasty for old tuberculosis of the knee. *J Bone Jt Surg Br* 1988;**70**:767–9.
- Baldini N, Toni A, Greggi T, Giunti A. Deep sepsis from Mycobacterium tuberculosis after total hip replacement. Case report. *Arch Orthop Trauma Surg* 1988;**107**:186–8.
- Gale DW, Harding ML. Total knee arthroplasty in the presence of active tuberculosis. *J Bone Jt Surg Br* 1991;**73**:1006–7.
- Spinner RJ, Sexton DJ, Goldner RD, Levin LS. Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. *J Arthroplast* 1996;**11**:217–22.
- Lusk RH, Wienke EC, Milligan TW, Albus TE. Tuberculous and foreign-body granulomatous reactions involving a total knee prosthesis. *Arthritis Rheum* 1995;**38**:1325–7.
- Tokumoto JI, Follansbee SE, Jacobs RA. Prosthetic joint infection due to Mycobacterium tuberculosis: report of three cases. *Clin Infect Dis* 1995; 21:134–136.
- Ueng WN, Shih CH, Hseuh S. Pulmonary tuberculosis as a source of infection after total hip arthroplasty. A report of two cases. *Int Orthop* 1995;**19**:55–9.
- Kreder HJ, Davey JR. Total hip arthroplasty complicated by tuberculous infection. *J Arthroplast* 1996;**11**:111–14.
- Carlsson AS, Sanzén L. Bilateral tuberculous infection of replaced hips—reactivation 54 years after infection in one knee. *Acta Orthop Scand* 1997;**68**:70–6.
- Berbari EF, Hanssen AD, Duffy MC, Steckelberg JM, Osmon DR. Prosthetic joint infection due to Mycobacterium tuberculosis: a case series and review of the literature. *Am J Orthop* 1998;**27**:219–27.

32. Krappel FA, Harland U. Failure of osteosynthesis and prosthetic joint infection due to Mycobacterium tuberculosis following a subtrochanteric fracture: a case report and review of the literature. *Arch Orthop Trauma Surg* 2000;**120**:470–2.
33. Hugate R, Pellegrini VD. Reactivation of ancient tuberculous arthritis of the hip following total hip arthroplasty: a case report. *J Bone Jt Surg Am* 2002;**84-A**:101–5.
34. Boeri C, Gaudias J, Jenny JY. Total hip replacement complicated by tuberculous infection. *Rev Chir Orthop Reparatrice Appar Mot* 2003;**89**:163–6.
35. Fernandez-Valencia JA, Garcia S, Riba J. Presumptive infection of a total hip prosthesis by Mycobacterium tuberculosis: a case report. *Acta Orthop Belg* 2003;**69**:193–6.
36. Al-Shaikh R, Goodman SB. Delayed-onset Mycobacterium tuberculosis infection with staphylococcal superinfection after total knee replacement. *Am J Orthop* 2003;**32**:302–5.
37. Marmor M, Parnes N, Dekel S. Tuberculosis infection complicating total knee arthroplasty. *J Arthroplast* 2004;**19**:397–400.
38. Kaya M, Nagoya S, Yamashita T, Niino N, Fujita M. Peri-prosthetic tuberculous infection of the hip in a patient with no previous history of tuberculosis. *J Bone Jt Surg Br* 2006;**88**:394–5.
39. Kadakia AP, Williams R, Langkamer VG. Tuberculous infection in a total knee replacement performed for medial tibial plateau fracture: a case report. *Acta Orthop Belg* 2007;**73**:661–4.
40. Khater FJ, Samnani IQ, Mehta JB, Moorman JP, Myers JW. Prosthetic joint infection by Mycobacterium tuberculosis: an unusual case report with literature review. *South Med J* 2007;**100**:66–9.
41. Shanbhag V, Kotwal R, Gaitonde A, Singhal K. Total hip replacement infected with Mycobacterium tuberculosis. A case report with review of literature. *Acta Orthop Belg* 2007;**73**:268–74.
42. Wang P-H, Shih K-S, Tsai C-C, Wang H-C. Pulmonary tuberculosis with delayed tuberculosis infection of total knee arthroplasty. *J Formos Med Assoc* 2007;**106**:82–5.
43. de Haan J, Vreeling AWJ, van Hellemond G. Reactivation of ancient joint tuberculosis of the knee following total knee arthroplasty after 61 years: a case report. *Knee* 2008;**15**:336–8.
44. Marshall J, Evison JM, Droz S, Studer UC, Zimmerli S. Disseminated tuberculosis following total knee arthroplasty in an HIV patient. *Infection* 2008;**36**:274–8.
45. Lee C-L, Wei Y-S, Ho Y-J, Lee C-H. Postoperative Mycobacterium tuberculosis infection after total knee arthroplasty. *Knee* 2009;**16**:87–9.
46. Neogi DS, Kumar A, Yadav CS, Singh S. Delayed periprosthetic tuberculosis after total knee replacement: is conservative treatment possible? *Acta Orthop Belg* 2009;**75**:136–40.
47. Upton A, Woodhouse A, Vaughan R, Newton S, Ellis-Pegler R. Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host. *J Clin Microbiol* 2009;**47**:507–10.
48. Mete B. An unusual cause of prosthetic joint infection: Mycobacterium tuberculosis. *JMID* 2012;**2**:72–5.
49. De Nardo P, Corpolongo A, Conte A, Gentilotti E, Narciso P. Total hip replacement infected with Mycobacterium tuberculosis complicated by Addison disease and psoas muscle abscess: a case report. *J Med Case Rep* 2012;**6**:3 Available at: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22233936&retmode=ref&cmd=prlinks>.
50. Klein GR, Jacquette GM. Prosthetic knee infection in the young immigrant patient—do not forget tuberculosis!. *J Arthroplast* 2012;**27**(1414):e1–4.
51. Carrega G, Bartolacci V, Burastero G, Finocchio GC, Ronca A, Riccio G. Case report – open access. *Int J Surg Case Rep* 2013;**4**:178–81.
52. Harwin SF, Banerjee S, Issa K, Kapadia BH, Pivec R, Khanuja HS, et al. Tubercular prosthetic knee joint infection. *Orthopedics* 2013;**36**:e1464–9.
53. Tekin Koruk S. Periprosthetic tuberculosis of the knee joint treated with antituberculosis drugs: a case report. *Acta Orthop Traumatol Turc* 2013;**47**:440–3.
54. Keudell von A, Nathavitharana R, Yassa D, Abdeen A. An unusual pathogen for prosthetic joint infection. *Lancet Infect Dis* 2016;**16**:506.
55. Brennan MJ. Biofilms and Mycobacterium tuberculosis. *Infect Immun* 2017;**85**:e00411–17.
56. Ha K-Y, Chung Y-G, Ryoo S-J. Adherence and biofilm formation of *Staphylococcus epidermidis* and *Mycobacterium tuberculosis* on various spinal implants. *Spine* 2005;**30**:38–43.
57. Chen W-H, Jiang L-S, Dai L-Y. Influence of bacteria on spinal implant-centered infection. *Spine* 2011;**36**:103–8.